Q1 Earnings Estimate for IO Biotech Issued By HC Wainwright

IO Biotech, Inc. (NASDAQ:IOBT) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of IO Biotech in a report issued on Tuesday, April 1st. HC Wainwright analyst E. Bodnar expects that the company will post earnings per share of ($0.50) for the quarter. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for IO Biotech’s current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for IO Biotech’s Q1 2025 earnings at ($0.50) EPS, Q2 2025 earnings at ($0.51) EPS, Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.42) EPS, FY2025 earnings at ($1.42) EPS, FY2026 earnings at ($0.91) EPS, FY2026 earnings at ($0.91) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.39) EPS, FY2028 earnings at ($0.39) EPS, FY2029 earnings at ($0.13) EPS and FY2029 earnings at ($0.13) EPS.

Separately, Piper Sandler raised IO Biotech to a “strong-buy” rating in a report on Wednesday, March 12th.

IO Biotech Stock Down 2.1 %

Shares of IOBT opened at $0.98 on Friday. The company has a 50-day moving average price of $0.97 and a two-hundred day moving average price of $0.98. The stock has a market cap of $64.84 million, a price-to-earnings ratio of -0.72 and a beta of 0.08. IO Biotech has a 12 month low of $0.66 and a 12 month high of $1.79.

Institutional Investors Weigh In On IO Biotech

Several large investors have recently made changes to their positions in the company. Dauntless Investment Group LLC bought a new position in IO Biotech during the 4th quarter valued at about $688,000. Landscape Capital Management L.L.C. acquired a new stake in shares of IO Biotech during the fourth quarter worth approximately $407,000. Citadel Advisors LLC bought a new position in shares of IO Biotech in the fourth quarter valued at approximately $249,000. Renaissance Technologies LLC boosted its holdings in shares of IO Biotech by 22.5% in the 4th quarter. Renaissance Technologies LLC now owns 118,800 shares of the company’s stock worth $109,000 after acquiring an additional 21,800 shares in the last quarter. Finally, Vontobel Holding Ltd. acquired a new position in shares of IO Biotech in the 4th quarter worth approximately $30,000. Institutional investors own 54.76% of the company’s stock.

IO Biotech Company Profile

IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.